{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:06:29Z","timestamp":1748469989627},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00428-018-2480-4","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T13:28:11Z","timestamp":1541597291000},"page":"71-78","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BRAF mutation testing in melanoma: results from a German observational multicenter study"],"prefix":"10.1007","volume":"474","author":[{"given":"Arndt","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Sterlacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Liesenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Schif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"key":"2480_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","volume":"6","author":"MJ Garnett","year":"2004","unstructured":"Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313\u2013319. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2004.09.022","journal-title":"Cancer Cell"},{"key":"2480_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. \n                    https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"2480_CR3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","volume":"164","author":"JH Lee","year":"2011","unstructured":"Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776\u2013784. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10185.x","journal-title":"Br J Dermatol"},{"key":"2480_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J, Nickerson E, Auclair D, Li L, Place C (2012) A landscape of driver mutations in melanoma. Cell 150:251\u2013263. \n                    https:\/\/doi.org\/10.1016\/j.cell.2012.06.024","journal-title":"Cell"},{"key":"2480_CR5","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014\u20134023. \n                    https:\/\/doi.org\/10.1002\/cncr.26724","journal-title":"Cancer"},{"key":"2480_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/PAI.0000000000000013","volume":"22","author":"L Ehsani","year":"2014","unstructured":"Ehsani L, Cohen C, Fisher KE, Siddiqui MT (2014) BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. Appl Immunohistochem Mol Morphol 22:648\u2013651. \n                    https:\/\/doi.org\/10.1097\/PAI.0000000000000013","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"Suppl. 5","key":"2480_CR7","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, ESMO Guidelines Committee (2015) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl. 5):v126\u2013v132. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv297","journal-title":"Ann Oncol"},{"key":"2480_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"2480_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358\u2013365. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"key":"2480_CR10","unstructured":"Zelboraf\u00ae (vemurafenib). Summary of product characteristics. In:. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002409\/WC500124317.pdf\n                    \n                  . Accessed Feb 2018"},{"key":"2480_CR11","unstructured":"Tafinlar\u00ae (dabrafenib). Summary of product characteristics. In:. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002604\/WC500149671.pdf\n                    \n                  . Accessed Feb 2018"},{"key":"2480_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/PAT.0b013e3283532565","volume":"44","author":"B Amanuel","year":"2012","unstructured":"Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B (2012) Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 44:357\u2013359. \n                    https:\/\/doi.org\/10.1097\/PAT.0b013e3283532565","journal-title":"Pathology"},{"key":"2480_CR13","doi-asserted-by":"publisher","first-page":"e0153576","DOI":"10.1371\/journal.pone.0153576","volume":"11","author":"A Harl\u00e9","year":"2016","unstructured":"Harl\u00e9 A, Salleron J, Franczak C, Dubois C, Filhine-Tressarieu P, Leroux A, Merlin JL (2016) Detection of BRAF mutations using a fully automated platform and comparison with high resolution melting, real-time allele specific amplification, immunohistochemistry and next generation sequencing assays, for patients with metastatic melanoma. PLoS One 11:e0153576. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0153576","journal-title":"PLoS One"},{"key":"2480_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239\u20131246. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.32.4327","journal-title":"J Clin Oncol"},{"key":"2480_CR15","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18:3242\u20133249. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0052","journal-title":"Clin Cancer Res"},{"key":"2480_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jmoldx.2013.07.003","volume":"15","author":"K Qu","year":"2013","unstructured":"Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, Nguyen D, Jones D, Waldman F (2013) Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn 15:790\u2013795. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2013.07.003","journal-title":"J Mol Diagn"},{"key":"2480_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ajco.12574","volume":"12","author":"WK Huang","year":"2016","unstructured":"Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW (2016) A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. Asia Pac J Clin Oncol 12:403\u2013408. \n                    https:\/\/doi.org\/10.1111\/ajco.12574","journal-title":"Asia Pac J Clin Oncol"},{"key":"2480_CR18","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Carac\u00f2 C, Mozzillo N, Ascierto PA, Palmieri G (2012) BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522\u20132529. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.41.2452","journal-title":"J Clin Oncol"},{"key":"2480_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/sj.bjc.6600919","volume":"88","author":"SC Edmunds","year":"2003","unstructured":"Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88:1403\u20131405. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600919","journal-title":"Br J Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2480-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2480-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:21:34Z","timestamp":1573086094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2480-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2480-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A Hartmann has received research funding from Sysmex, BioNTech, Nanostring, and Novartis, and has received honoraria from Roche, AstraZeneca, BMS, and MSD, and payment for consultancy or advisory roles from Medoc, Roche, AstraZeneca, BMS, and MSD. P Schirmacher has received research funding from Roche, AstraZeneca, Novartis, Chugai, Thermo Fisher, and Sanofi Aventis, honoraria from Novartis, AstraZeneca, and Roche, and payment for consultancy or advisory roles from Roche, AstraZeneca, Novartis, BMS, MSD, Merck, and Amgen. W Sterlacci has received payment for consultancy or advisory roles from Roche. W Koch is an employee of BDS Koch, which receives payment for statistical services from Roche. B Schif and DB Liesenfeld are employed by Roche. C Garbe has received research funding from BMS, Novartis, and Roche, honoraria from Amgen, BMS, MSD, Novartis, and Roche, travel, accommodation, and other expenses from Amgen, BMS, MSD, Novartis, and Roche, and payment for consultancy or advisory roles from Amgen, BMS, MSD, Novartis, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained at the University of Erlangen-N\u00fcrnberg (approval no. 14_13 B dated Feb 19th 2013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required as all data were collected as part of routine testing and were fully anonymized prior to analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}